BACKGROUND AND PURPOSE: Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for treating anemia. In animal models, exogenous recombinant human erythropoietin has been reported to be beneficial in treating experimental cerebral ischemia. In this study, we determined whether darbepoetin alfa would protect in a rat model of transient focal cerebral ischemia. METHODS: Rats received 2-hour middle cerebral artery suture-occlusion. The drug (darbepoetin alfa, 10 microg/kg) or vehicle was administered intraperitoneally 2 hours after onset of middle cerebral artery occlusion. Animals were allowed to survive for 3 or 14 days. Behavioral tests were performed sequentially. Infarct volumes and brain swelling were determined. RESULTS: Darbepoetin alfa-treated rats showed improved neuroscores relative to vehicle-treated animals beginning within 1 hour of treatment and persisting throughout the 14-day survival period. Darbepoetin alfa significantly reduced corrected total (cortical + subcortical) infarct volume (56.3+/-20.6 and 110.8+/-6.8 mm3, respectively) and total infarct areas at multiple levels compared with vehicle in the 14-day survival group. Brain swelling was not affected by treatment. CONCLUSIONS: Darbepoetin alfa confers behavioral and histological neuroprotection after focal ischemia in rats.
BACKGROUND AND PURPOSE: Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for treating anemia. In animal models, exogenous recombinant humanerythropoietin has been reported to be beneficial in treating experimental cerebral ischemia. In this study, we determined whether darbepoetin alfa would protect in a rat model of transient focal cerebral ischemia. METHODS:Rats received 2-hour middle cerebral artery suture-occlusion. The drug (darbepoetin alfa, 10 microg/kg) or vehicle was administered intraperitoneally 2 hours after onset of middle cerebral artery occlusion. Animals were allowed to survive for 3 or 14 days. Behavioral tests were performed sequentially. Infarct volumes and brain swelling were determined. RESULTS: Darbepoetin alfa-treated rats showed improved neuroscores relative to vehicle-treated animals beginning within 1 hour of treatment and persisting throughout the 14-day survival period. Darbepoetin alfa significantly reduced corrected total (cortical + subcortical) infarct volume (56.3+/-20.6 and 110.8+/-6.8 mm3, respectively) and total infarct areas at multiple levels compared with vehicle in the 14-day survival group. Brain swelling was not affected by treatment. CONCLUSIONS: Darbepoetin alfa confers behavioral and histological neuroprotection after focal ischemia in rats.
Authors: Peter Kanellakis; Giovanna Pomilio; Alex Agrotis; Xiaoming Gao; Xiao-Jun Du; David Curtis; Alexander Bobik Journal: Br J Pharmacol Date: 2010-08 Impact factor: 8.739
Authors: Shaida A Andrabi; No Soo Kim; Seong-Woon Yu; Hongmin Wang; David W Koh; Masayuki Sasaki; Judith A Klaus; Takashi Otsuka; Zhizheng Zhang; Raymond C Koehler; Patricia D Hurn; Guy G Poirier; Valina L Dawson; Ted M Dawson Journal: Proc Natl Acad Sci U S A Date: 2006-11-20 Impact factor: 11.205
Authors: Mariana C Baserga; Joanna C Beachy; Jessica K Roberts; Robert M Ward; Robert J DiGeronimo; William F Walsh; Robin K Ohls; Jennifer Anderson; Dennis E Mayock; Sandra E Juul; Robert D Christensen; Manndi C Loertscher; Chris Stockmann; Catherine M T Sherwin; Michael G Spigarelli; Bradley A Yoder Journal: Pediatr Res Date: 2015-05-21 Impact factor: 3.756
Authors: Marco Inzitari; Stephanie Studenski; Caterina Rosano; Neil A Zakai; William T Longstreth; Mary Cushman; Anne B Newman Journal: J Am Geriatr Soc Date: 2008-09-22 Impact factor: 5.562
Authors: Robin K Ohls; Robert D Christensen; Beena D Kamath-Rayne; Adam Rosenberg; Susan E Wiedmeier; Mahshid Roohi; Conra Backstrom Lacy; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Ron Schrader; Jean R Lowe Journal: Pediatrics Date: 2013-06-17 Impact factor: 7.124
Authors: Pia Villa; Sara Triulzi; Barbara Cavalieri; Rosa Di Bitondo; Riccardo Bertini; Sara Barbera; Paolo Bigini; Tiziana Mennini; Paolo Gelosa; Elena Tremoli; Luigi Sironi; Pietro Ghezzi Journal: Mol Med Date: 2007 Mar-Apr Impact factor: 6.354